These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 32421966)

  • 1. Gut Microbiota and Metabolic Disorders: Advances in Therapeutic Interventions.
    Akash MSH; Fiayyaz F; Rehman K; Sabir S; Rasool MH
    Crit Rev Immunol; 2019; 39(4):223-237. PubMed ID: 32421966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota and short chain fatty acids partially mediate the beneficial effects of inulin on metabolic disorders in obese ob/ob mice.
    Guo J; Zhang M; Wang H; Li N; Lu Z; Li L; Hui S; Xu H
    J Food Biochem; 2022 May; 46(5):e14063. PubMed ID: 35128673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
    Halmos T; Suba I
    Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probiotics, prebiotics, synbiotics and insulin sensitivity.
    Kim YA; Keogh JB; Clifton PM
    Nutr Res Rev; 2018 Jun; 31(1):35-51. PubMed ID: 29037268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
    Amabebe E; Robert FO; Agbalalah T; Orubu ESF
    Br J Nutr; 2020 May; 123(10):1127-1137. PubMed ID: 32008579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?
    Sircana A; Framarin L; Leone N; Berrutti M; Castellino F; Parente R; De Michieli F; Paschetta E; Musso G
    Curr Diab Rep; 2018 Sep; 18(10):98. PubMed ID: 30215149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the microbiome in the management of children with type 2 diabetes mellitus.
    Brar PC; Kohn B
    Curr Opin Pediatr; 2019 Aug; 31(4):524-530. PubMed ID: 31299021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of diet and intestinal microbiota in the development of metabolic syndrome.
    Santos-Marcos JA; Perez-Jimenez F; Camargo A
    J Nutr Biochem; 2019 Aug; 70():1-27. PubMed ID: 31082615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
    Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
    Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota.
    Wang Y; Liu H; Zheng M; Yang Y; Ren H; Kong Y; Wang S; Wang J; Jiang Y; Yang J; Shan C
    Front Endocrinol (Lausanne); 2021; 12():609134. PubMed ID: 34025574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting gut microbiota as a possible therapy for diabetes.
    He C; Shan Y; Song W
    Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
    Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
    Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections.
    Serino M
    J Mol Biol; 2018 Mar; 430(5):581-590. PubMed ID: 29374557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut Microbiota and Gestational Diabetes Mellitus: A Review of Host-Gut Microbiota Interactions and Their Therapeutic Potential.
    Hasain Z; Mokhtar NM; Kamaruddin NA; Mohamed Ismail NA; Razalli NH; Gnanou JV; Raja Ali RA
    Front Cell Infect Microbiol; 2020; 10():188. PubMed ID: 32500037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study.
    Chu JR; Kang SY; Kim SE; Lee SJ; Lee YC; Sung MK
    World J Gastroenterol; 2019 Oct; 25(40):6129-6144. PubMed ID: 31686768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases.
    Zeng Y; Wu Y; Zhang Q; Xiao X
    mBio; 2024 Jan; 15(1):e0203223. PubMed ID: 38055342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus.
    Duan L; An X; Zhang Y; Jin D; Zhao S; Zhou R; Duan Y; Zhang Y; Liu X; Lian F
    Biomed Pharmacother; 2021 Oct; 142():112094. PubMed ID: 34449321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.